- Home
- TSI vs CANF Comparison
TSI vs CANF Comparison
Compare TSI & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSI
- CANF
- Stock Information
- Founded
- TSI 1987
- CANF 1994
- Country
- TSI United States
- CANF Israel
- Employees
- TSI N/A
- CANF N/A
- Industry
- TSI Investment Managers
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- TSI Finance
- CANF Health Care
- Exchange
- TSI Nasdaq
- CANF Nasdaq
- Market Cap
- TSI N/A
- CANF 7.9M
- IPO Year
- TSI N/A
- CANF N/A
- Fundamental
- Price
- TSI $4.86
- CANF $1.13
- Analyst Decision
- TSI
- CANF Strong Buy
- Analyst Count
- TSI 0
- CANF 2
- Target Price
- TSI N/A
- CANF $14.00
- AVG Volume (30 Days)
- TSI 106.8K
- CANF 413.7K
- Earning Date
- TSI 01-01-0001
- CANF 05-06-2025
- Dividend Yield
- TSI 7.46%
- CANF N/A
- EPS Growth
- TSI N/A
- CANF N/A
- EPS
- TSI N/A
- CANF N/A
- Revenue
- TSI N/A
- CANF $674,000.00
- Revenue This Year
- TSI N/A
- CANF $461.72
- Revenue Next Year
- TSI N/A
- CANF N/A
- P/E Ratio
- TSI N/A
- CANF N/A
- Revenue Growth
- TSI N/A
- CANF N/A
- 52 Week Low
- TSI $4.48
- CANF $1.22
- 52 Week High
- TSI $4.87
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- TSI 52.12
- CANF 35.40
- Support Level
- TSI $4.71
- CANF $1.14
- Resistance Level
- TSI $4.84
- CANF $1.27
- Average True Range (ATR)
- TSI 0.08
- CANF 0.12
- MACD
- TSI 0.00
- CANF -0.02
- Stochastic Oscillator
- TSI 83.33
- CANF 0.00
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).